Netherlands· NL-0fc6d426f611
Ryeqo 40 mg/1 mg/0.5 mg, filmomhulde tabletten
A relugolix, estradiol und norethisteron product containing estradiol 0,5-water + norethisteronacetaat + relugolix, registered in Netherlands by Gedeon Richter Plc. The same ATC class is registered in 11 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Relugolix, estradiol und norethisteron is registered in 11 of 19 countries.
Countries holding a registration under ATC H01CC54 (relugolix, estradiol und norethisteron), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 7 of them publish a price we can compare per daily dose
Relugolix, estradiol und norethisteron · ATC H01CC54
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- ESTRADIOL 0,5-WATER + NORETHISTERONACETAAT + RELUGOLIX
- Manufacturer
- Gedeon Richter Plc
- Country
- Netherlands (NL)
- ATC code
- H01CC54
- ATC class
- Relugolix, Estradiol und Norethisteron
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/21/1565
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Relugolix, estradiol und norethisteron in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandRyeqo, FilmtablettenGedeon Richter (Schweiz) AG
- NorwayRyeqoOrifarm AS
- CanadaMYFEMBREESUMITOMO PHARMA SWITZERLAND GMBH
- PolandRyeqoGedeon Richter Plc.
- SwedenRyeqo 40 mg/1 mg/0,5 mg Filmdragerad tablettGedeon Richter Plc
- United KingdomRyeqo 40mg/1mg/0.5mg tabletsGedeon Richter (UK) Ltd
- SpainRYEQO 40 MG/1 MG/0,5 MG COMPRIMIDOS RECUBIERTOS CON PELICULAGedeon Richter Plc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ryeqo
- Liechtenstein · Ryeqo
- Norway · Ryeqo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9efb30f6-1afa-4262-8e32-d0fd714128dc GET /v1/drugs/9efb30f6-1afa-4262-8e32-d0fd714128dc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/ryeqo-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Relugolix, Estradiol And Norethisterone",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp126460",
"excipients": [
"GLYCEROLTRIACETAAT (E 1518)",
"HYPROLOSE (E 463)",
"HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
"IJZEROXIDE GEEL (E 172)",
"LACTOSE 1-WATER",
"MAGNESIUMSTEARAAT (E 470b)",
"MANNITOL (D-) (E 421)",
"NATRIUMZETMEELGLYCOLAAT",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"ESTRADIOL 0,5-WATER",
"NORETHISTERONACETAAT",
"RELUGOLIX"
],
"leaflet_url": null,
"authorised_at": "2021/07/16",
"procedure_number": "EMEA/H/C/005267",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/21/1565",
"additional_monitoring": "N"
}See everything about relugolix, estradiol und norethisteron.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.